Win Advisors’s DexCom DXCM Stock Holding History

Win Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,701	Closed	-$799K	–	58
2025 Q1	$799K	Buy	+11,701	New	+$955K	0.41%	48

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Win Advisors's DXCM Position: Q2 2025 in Review

Win Advisors sold out of DexCom (DXCM) in Q2 2025, closing a stake of 11,701 shares — an estimated $799K sold.

Win Advisors first reported a position in DXCM in Q1 2025 and held it in 1 quarter. The position peaked at $799K in Q1 2025. 939 funds tracked by Wall St. Rank hold DXCM as of Q2 2025.

Win Advisors reported no remaining DexCom position as of Q2 2025 after selling out during the quarter.
Win Advisors sold 11,701 DexCom shares in Q2 2025, an estimated $799K.
Win Advisors first reported a position in DexCom in Q1 2025 and held it in 1 quarter.
Win Advisors's DexCom position peaked at $799K in Q1 2025.
939 funds tracked by Wall St. Rank held DexCom as of Q2 2025.

Based on Win Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.